Abstract
Intracranial gliomas are the most prevalent form of primary brain tumors. The dynamic biology of these cancers compounded by their elusive location within the brain renders them very difficult to treat by means of conventional therapy. Despite continued advances in surgical and medical therapies, the outcome for patients diagnosed with this form of cancer remains in need of dramatic improvements. Gliomas, like many other forms of cancer, are subject to unpredictable genotypic and phenotypic alterations resulting in treatment resistant clones (Ehtesham et al., 2005). The selective permeability of the blood brain barrier limits the effectiveness of most chemotherapeutic agents, impeding their ability to reach distant tumor cells (Lesniak and Brem, 2004). Surgical treatment also faces many obstacles, as the biological nature of these tumors causes them to infiltrate diffusely within surrounding brain parenchyma (Ehtesham et al., 2005). In light of these challenges, novel techniques and alternative approaches are being explored to treat this terminal condition.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, Breakefield XO, Snyder EY (2000) Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 97:12846–12851
Aboody KS, Najbauer J, Danks MK (2008) Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther 15:739–752
Altaner C (2008) Glioblastoma and stem cells. Neoplasma 5:369–374
Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F, Kracher J, Grossman SA, Fisher JD, Carson K, Rosenblum M, Mikkelsen T, Olson J, Markert J, Rosenfeld S, Nabors LB, Brem S, Phuphanich S, Freeman S, Kaplan R, Zwiebel J (2004) A phase iopen-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas in the adjuvant setting. Mol Ther 10:958–966
Chu RL, Post DE, Khuri FR, Van Meir EG (2004) Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 10:5299–5312
Curiel DT, Douglas JT (2002) Adenoviral vectors for gene therapy. Elsevier Science,, San Diego CA
Das A, Tan WL, Teo J, Smith RD (2002) Expression of surviving in primary glioblastomas. J Cancer Res Clin Oncol 128:302–306
Ehtesham M, Stevenson CB, Thompson RB (2005) Stem cell therapies for malignant glioma. Neurosurg Focus 19:E5
Ehtesham M, Winston JA, Kabos P, Thompson RC (2006) CXCR4 expression mediates glioma cell invasiveness. Oncogene 25:2801–2806
Fueyo J, Gomez-Monzano C, Alemany R, Lee PSY, McDonnell TJ, Mitlianga P, Shi YX, Levin VA, Yung WKA, Kyritsis AP (2000) A mutant oncolytic adenovirus targeting the rb pathway produces anti-glioma effect in vivo. Oncogene 19:2–12
Fueyo J, Jiang H, Gomez-Monzano C, Aoki H, Alonso MH, Kondo S, McCormick F, Xu J, Kondo Y, Bekele N, Colman H, Lang FF (2007) Examination of the therapeutic potential of delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst 99:1410–1414
Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Terrier-Lacomb MJ, Bressac-de Paillerets B, Barrois M, Feunteun J, Kirn DH, Vassal G (2002) Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res 62:764–772
Hemmi S, Geertsen R, Mezzacasa A, Peter I, Dummer R (1998) The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther 16:2363–2373
Khalid S, Emilie B, Kim DE, Atherine Y, Yi T, Ralph W, Xandra OB (2005) Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Ann Neurol 57:34–41
Lemont JP, Nemunaitis J, Kuhn JA, Landers SA, McCarthy TM (2000) A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamos cell carcinoma of the head and neck (the baylor experience). Ann Surg Oncol 7:588–592
Lesniak MS, Brem H (2004) Targeted therapy for brain tumours. Nat Rev Drug Discov 3:499–508
Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentchel S, Vecil G, Dembinski J, Andreeff M, Lang FF (2005) Human bone marrow-derived medenchymal stem cells in the treatment of gliomas. Cancer Res 65:3307–3318
Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, Kuhn J, McCarty T, Landers S, Blackburn A, Romel L, Randlev B, Kaye S, Kirn D (2001) Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 19:289–298
Palmer DJ, Ng P (2008) Methods for the production of first generation adenoviral vectors. Methods Mol Bio 433:55–78
Ponte AL, Marais E, Gallay N, Langonné A, Delorme B, Hérault O, Charbord P, Domenech J (2007) The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 25:1737–1745
Pulkkanen KJ, Yla-Herttuala S (2005) Gene therapy for malignant glioma: current clinical status. Mol Ther 12:585–598
Sonabend AM, Ulasov IV, Lesniak MS (2007) Gene therapy trials for the treatment of high grade gliomas. Gene Ther Mol Biol 11:79–92
Sonabend AM, Ulasov IV, Tyler MA, Rivera AA, Mathis JM, Lesniak MS (2008) Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 26:831–841
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 10:987–996
Tyler MA, Ulasov IV, Sonabend AM, Nandi S, Marler S, Roth J, Lesniak MS (2009) Neural stemcells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther 16(2):262–278
Ulasov IV, Tyler MA, Rivera AA, Nettlebeck DM, Douglas JT, Lesniak MS (2008) Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy. Med Virol 80:1595–1603
Ulasov IV, Zhu ZB, Tyler MA, Han Y, Rivera AA, Khramtsov A, Curiel DT, Lesniak MS (2007) Survivin-driven and fiber-modified adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther 18(7):599–602
Van Houdt WJ, Haviv YS, Lu B, Wang M, Rivera AA, Ulasov IV, Lamfers ML, Rein D, Lesniak MS, Siegal GP, Dirven CM, Curiel DT, Zhu ZB (2006) The human surviving promoter: a novel transcriptional targeting strategy for treatment of glioma. J Neurosurg 104:583–592
Vecil GG, Lang FF (2003) Clinical trials of adenoviruses in brain tumors: a review of ad-p53 and oncolytic adenoviruses. J Neuro-Oncol 65:237–246
Zheng S, Ulasov IV, Han Y, Tyler MA, Zhu ZB,, Lesniak MS (2007) Fiber knob modifications enhance adenoviral tropism and gene transfer in malignant glioma. J Gene Med 9:151–160
Zhenggang Z, Quan J, Feng J, Guangliang D, Ruilan Z, Lei W, Li Z, Adam MR, Mark K, Michael C (2004) In vivo magnetic resonance imaging tracks adult neural progenitor cell targeting of brain tumor. NeuroImage 23:281–287
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Kranzler, J., Tyler, M.A., Ulasov, I.V., Lesniak, M.S. (2011). Intracranial Glioma: Delivery of an Oncolytic Adenovirus. In: Hayat, M. (eds) Tumors of the Central Nervous System, Volume 1. Tumors of the Central Nervous System, vol 1. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-0344-5_38
Download citation
DOI: https://doi.org/10.1007/978-94-007-0344-5_38
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-0343-8
Online ISBN: 978-94-007-0344-5
eBook Packages: MedicineMedicine (R0)